Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Omega Funds
AddedFeb 13, 2024
UpdatedJun 28, 2026
Omega Funds

Omega Funds

Operating

Omega Funds: A global life sciences investment firm targeting urgent medical needs.

Location
Boston, MA, US
Founded
2004
Firm
Compare
Portfolio
Employees

Investments

Bicara Therapeutics
Bicara Therapeutics

Total Raised

$313M

Rounds

3

Series C$165MDecember 2023
Series B$108MMarch 2023
Artbio
Artbio

Total Raised

$113M

Rounds

2

Series A$90MDecember 2023
Seed$23MJune 2023
Beta Bionics
Beta Bionics

Total Raised

$293.5M

Rounds

8

Series D$100MAugust 2023
Upstream Bio
Upstream Bio

Total Raised

$408M

Rounds

4

Series B$200MJune 2023
Series A$200MJune 2022
Chroma Medicine
Chroma Medicine

Total Raised

$260M

Rounds

3

Series B$135MMarch 2023
Series A$125MNovember 2021
Photys Therapeutics
Photys Therapeutics

Total Raised

$75M

Rounds

1

Series A$75MSeptember 2022
Endeavor Biomedicines
Endeavor Biomedicines

Total Raised

$163M

Rounds

2

Series B$101MFebruary 2022
Series A$62MJanuary 2021
Rectify Pharmaceuticals
Rectify Pharmaceuticals

Total Raised

$100M

Rounds

1

Series A$100MOctober 2021
Thankful
Thankful

Total Raised

$12M

Rounds

3

Series A$12MSeptember 2021
Alpine Immune Sciences
Alpine Immune Sciences
Acquired

Total Raised

$475.3M

Rounds

8

Post Ipo Equity$91MSeptember 2021
Post Ipo Equity$60MJuly 2020
Vanqua Bio
Vanqua Bio

Total Raised

$85M

Rounds

2

Series B$85MSeptember 2021
Synthekine
Synthekine

Total Raised

$289.5M

Rounds

3

Series B$107.5MJune 2021
Scorpion Therapeutics
Scorpion Therapeutics

Total Raised

$270M

Rounds

2

Series B$162MJanuary 2021
Series A$108MOctober 2020
ImageneBio
ImageneBio
Public

Total Raised

$209M

Rounds

4

Series B$120MJanuary 2021
Syros Pharmaceuticals
Syros Pharmaceuticals
Public

Total Raised

$620.5M

Rounds

12

Post Ipo Equity$90.5MDecember 2020
Kronos Bio
Kronos Bio
Public

Total Raised

$278M

Rounds

4

Private Equity$155MAugust 2020
Atea Pharmaceuticals
Atea Pharmaceuticals
Public

Total Raised

$283.4M

Rounds

5

Series D$215MMay 2020
Spruce Biosciences
Spruce Biosciences
Public

Total Raised

$161.6M

Rounds

4

Series B$88MFebruary 2020